GESTIÓN EN SALUD PÚBLICA: Melanoma/Skin Cancer Detection and Prevention Month® (see related measures) 2 | National Quality Measures Clearinghouse 2/3

aportes a la gestión necesaria para la sustentabilidad de la SALUD PÚBLICA como figura esencial de los servicios sociales básicos para la sociedad humana, para la familia y para la persona como individuo que participa de la vida ciudadana.

GESTIÓN EN SALUD PÚBLICA

martes, 1 de mayo de 2018

Melanoma/Skin Cancer Detection and Prevention Month® (see related measures) 2 | National Quality Measures Clearinghouse 2/3

Health Awareness Topics: May 2018

Cutaneous melanoma: proportion of patients with cutaneous melanoma undergoing wide local excision within 84 days of their partial biopsy.

Cutaneous melanoma: proportion of patients with unresectable stage III and IV cutaneous melanoma who undergo systemic anti-cancer therapy (SACT).

Melanoma: percentage of patients who undergo a sentinel lymph node biopsy (SLNB) or lymph node dissection (LND) for melanoma for whom the pathology report documents the number of lymph nodes examined and the number of lymph nodes found to contain metastases.

Importance of Quality Metrics for Providing High Quality Melanoma Care

Melanoma: percentage of patients who undergo an inguinal lymph node dissection (LND) or completion lymph node dissection (CLND) for melanoma for whom at least five regional lymph nodes are resected and pathologically examined.

Melanoma: percentage of patients with melanoma and clinically apparent/palpable lymphadenopathy for whom a lymph node dissection (LND) is performed without an antecedent histologic diagnosis.

Cutaneous melanoma: proportion of patients with cutaneous melanoma undergoing clinical examination of relevant draining lymph node basins as part of clinical staging.

Melanoma: is the surgeon who performs sentinel lymph node biopsy (SLNB) or lymph node dissection (LND) for melanoma certified by the American Board of Surgery or equivalent board or international association?

Melanoma: percentage of patients who have stages 0, I, or IIA melanoma for whom an abdominal CT/MRI, pelvic CT/MRI, or PET scan was not performed, except in response to specific signs or symptoms.

Cutaneous melanoma: proportion of patients with cutaneous melanoma undergoing partial biopsy who undergo a wide local excision.

Cutaneous melanoma: proportion of patients with cutaneous melanoma who have their diagnostic excision biopsy carried out by a skin cancer clinician.

Melanoma: percentage of patients, regardless of age, with a current diagnosis of melanoma or a history of melanoma whose information was entered, at least once within the 12 month period, into a recall system.

Melanoma: percentage of patients with a melanoma for whom a clear histologic margin is documented.

Melanoma: percentage of patients with melanoma who have a metastatic lymph node detected on sentinel lymph node biopsy (SLNB) for whom a complete lymph node dissection (CLND) is performed except in the context of a clinical trial or if the patient has severe comorbidities.

Melanoma: percentage of patients with a melanoma greater than or equal to 2 mm thick (i.e., T3 or T4) for whom the surgical excision margins are 2-3 cm (or the specific anatomic or cosmetic factors that limit margin distance are noted).

Melanoma: percentage of patients who undergo a cervical lymph node dissection (LND) or completion lymph node dissection (CLND) for melanoma for whom at least 15 regional lymph nodes are resected and pathologically examined.

Cutaneous melanoma: proportion of patients with unresectable stage III or IV cutaneous melanoma who have their BRAF status checked.

Cutaneous melanoma: proportion of patients with cutaneous melanoma undergoing groin block dissection who have been referred to a lymphoedema service.

Melanoma: percentage of patients newly diagnosed with stage IV melanoma for whom a serum lactate dehydrogenase (LDH) level is measured.

No hay comentarios:

Publicar un comentario